ライフサイエンスコーパス: upper respiratory infection

1 carriage or a less severe syndrome, such as upper respiratory infection).

2 st moderate or severe exacerbation and first upper respiratory infection.

3 ive retinopathy, migraine disorder, and post-upper respiratory infection.

4 atent varicella and the other due to a viral upper respiratory infection.

5 The only predictor of FCA was recent upper respiratory infection.

6 ific symptoms strongly indicative of a viral upper respiratory infection.

7 influenza; tuberculosis; and other lower and upper respiratory infections.

8 influenza; tuberculosis, and other lower and upper respiratory infections.

9 of moderate or severe COPD exacerbations and upper respiratory infections.

10 e cough and other symptoms in the setting of upper respiratory infections.

11 ntinue to be prescribed indiscriminately for upper respiratory infections.

12 United States to boost immunity and prevent upper respiratory infections.

13 asthma, atopic dermatitis, food allergy, and upper respiratory infections.

14 initis, atopic dermatitis, food allergy, and upper respiratory infections.

15 rmation on the topics of atopic diseases and upper respiratory infections.

16 rmation on the topics of atopic diseases and upper respiratory infections.

17 nasopharyngeal niche, a reservoir for ME and upper respiratory infections.

18 , 95% CI 0.60-1.24, p=0.42) or time to first upper respiratory infection (0.95, 0.69-1.31, p=0.75).

19 8 [0.64-0.94], I(2) 64%; 12 comparisons) and upper respiratory infections (0.74 [0.59-0.93], I(2) 91%

20 rovascular disease (0.98 [0.96-1.01]), acute upper respiratory infection (1.03 [0.96-1.09]), and chro

21 ose of R788 vs. 3% of those taking placebo), upper respiratory infections (14% vs. 7%), and neutropen

22 3), rash (23/3), decreased appetite (20/15), upper respiratory infection (20/0), pneumonia (13/10), a

23 The most common adverse events were upper respiratory infections (20 events in 19 [15%] part

24 n tests (31.0% v 25.7%), and antibiotics for upper respiratory infections (36.6% v 32.7%; all P<0.001

25 associated with increased susceptibility to upper respiratory infection-a major precipitant of exace

26 controlled for meteorology, time trends, and upper respiratory infections, an increase of one interqu

27 ts; [2] antibiotic use: antibiotic for acute upper respiratory infection and antibiotic for influenza

28 reased risk for experimentally induced acute upper respiratory infection and clinical illness.

29 ycin provided significant protection against upper respiratory infection and lethal disease in a mous

30 Both PIV-3 upper respiratory infection and pneumonia were associate

31 rhinoviruses (HRV) are the leading cause of upper respiratory infections and have been postulated to

32 cilia is a potential therapeutic target for upper respiratory infections and that flavones may have

33 Reported fever, upper respiratory infection, and allergy were not associ

34 he most common adverse events were headache, upper respiratory infection, and fatigue.

35 No patients had a preceding upper respiratory infection, and only 1 patient had ante

36 Acute infections, particularly upper respiratory infections, and other inflammatory sti

37 lude early school age (5 to 9 years), recent upper respiratory infections, and sickle cell disease, w

38 , and avoiding antibiotics for patients with upper respiratory infections (APD, 2.05%; 95% CI, 1.17%-

39 t publications in the areas of sinusitis and upper respiratory infections are also reviewed.

40 he areas of allergic rhinoconjunctivitis and upper respiratory infections are also reviewed.

41 d allergy, allergic rhinoconjunctivitis, and upper respiratory infections are also reviewed.

42 actors such as asthma, the symptoms of acute upper respiratory infections are generally mild and self

43 way epithelial cells, causing bronchiolitis, upper respiratory infections, asthma exacerbations, chro

44 pronounced associations were seen for acute upper respiratory infections at multiple and unspecified

45 doctor to be due to a cold, otitis media, an upper respiratory infection, croup, asthma, bronchitis,

46 tional comparison group was defined by later upper respiratory infection diagnosis.

47 idence that acute otitis media occurs during upper respiratory infection, even in the absence of naso

48 by prevention of invasive disease and acute upper respiratory infections for vaccines with differing

49 arities in the manner in which children with upper respiratory infections have been traditionally man

50 t common adverse events were rash, transient upper respiratory infections, headache, and nausea.

51 reptococcus equi subspecies equi that causes upper respiratory infection in horses.

52 a capsulatum often results in a self-limited upper respiratory infection in humans; however, in immun

53 mentation for prevention of exacerbation and upper respiratory infection in patients with COPD are la

54 ied 409 children with asthma presenting with upper respiratory infection in the presence or absence o

55 tella bronchiseptica, the etiologic agent of upper respiratory infections in a wide range of mammalia

56 ugh prevention of invasive disease and acute upper respiratory infections in the United States.

57 nst moderate or severe exacerbation, but not upper respiratory infection, in patients with COPD with

58 .1 (95% CI, 182.1-182.1) and antibiotics for upper respiratory infections increased from 75.0 (95% CI

59 y outcomes were lower respiratory infection, upper respiratory infection, influenza confirmed by diag

60 Upper respiratory infection is a transient risk factor f

61 Parental history of children having upper respiratory infection is associated with increased

62 e 50 strain, is capable of causing a natural upper respiratory infection leading to death in mice, as

63 Soft Tissue Infections of the Head and Neck, Upper Respiratory Infections, Lower Respiratory Tract in

64 Soft Tissue Infections of the Head and Neck, Upper Respiratory Infections, Lower Respiratory Tract in

65 mperature, 102.7 +/- 0.32 degrees F), cough, upper respiratory infection, myalgia, and headache were

66 [5%]), pericardial effusion (n=2 [3%]), and upper respiratory infection (n=2 [3%]).

67 a (n = 237,833), pneumonia (n = 52,946), and upper respiratory infections (n = 414,556).

68 adverse events, the most common being viral upper respiratory infection (nine [11%] participants in

69 on, 60 (42%) with symptoms of pharyngitis or upper respiratory infection (no throat culture obtained)

70 iral respiratory infection (influenza, viral upper respiratory infection, nonsuppurative otitis media

71 ether HRV are detected during crises because upper respiratory infections often accompany asthma atta

72 Ten (53%) patients experienced upper respiratory infection or vaccination within 4 week

73 s: We recruited pregnant women who developed upper respiratory infections or tested positive for SARS

74 heeze (OR = 1.013; 95% CI: 1.003, 1.023) and upper respiratory infections (OR = 1.015; 95% CI: 1.008,

75 ancellation of surgery for the child with an upper respiratory infection, perioperative outcomes, and

76 fy the effect of the intervention on risk of upper respiratory infection (pinteraction=0.41).

77 Recent upper respiratory infection predicted cerebral arteriopa

78 Upper respiratory infections predominated (73.8%), follo

79 with the typical clinical syndrome of viral upper respiratory infection progressing to the lower res

80 nitis, influenza, pneumonia, and unspecified upper respiratory infections) recorded in ambulatory vis

81 Anesthesia for the child with an upper respiratory infection remains one of the most comm

82 the consolidation and maintenance group were upper respiratory infection (seven [8%] of 92 patients).

83 the influences of etiology (eg, head trauma, upper respiratory infection), sex, age, smoking behavior

84 ively associated with hospitalization, while upper respiratory infections showed a negative associati

85 ay that their initiating event began with an upper respiratory infection that progressed in both symp

86 iral infections are the most common cause of upper respiratory infections; they frequently infect adu

87 Costs of invasive GAS disease and acute upper respiratory infections totaled $6.08 (95% confiden

88 (three patients), nausea (two patients), and upper respiratory infections (two patients).

89 is (n = 80,399), pneumonia (n = 63,359), and upper respiratory infection (URI) (n = 359,246) among ch

90 ) the association between race/ethnicity and upper respiratory infection (URI) and (2) whether race/e

91 on was associated with a shorter duration of upper respiratory infection (URI) and overall use and av

92 in D supplementation (vs placebo) on risk of upper respiratory infection (URI) in older adults.

93 logic lesions in cats with clinical signs of upper respiratory infection (URI).

94 inusitis is a frequent complication of viral upper respiratory infection (URI).

95 usitis) or viral infection (influenza, viral upper respiratory infection [URI], bronchiolitis, bronch

96 Viral upper respiratory infections (URIs) are common and often

97 Outpatient antibiotic prescribing for acute upper respiratory infections (URIs) is a high-priority t

98 thma, chronic obstructive pulmonary disease, upper respiratory infections (URIs), and bronchitis, fro

99 l pediatric infections associated with viral upper respiratory infections (URIs).

100 ntribute to differences in susceptibility to upper respiratory infections (URIs).

101 hes from immunocompetent subjects during 146 upper respiratory infections (URIs); the sensitivities f

102 Antecedent upper respiratory infection was documented in 15 of 66 p

103 Incidence of upper respiratory infections was common throughout the s

104 lavage samples from building occupants with upper respiratory infections were also collected.

105 atric ED visits for asthma or wheeze and for upper respiratory infections were associated with PM2.5

106 rminally, he developed a rapidly progressive upper respiratory infection, which killed him in little

107 art disease (RHD) are autoimmune sequelae of upper respiratory infections with group A streptococci (